Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A Phase I/II Trial on Melphalan, Prednisone, Thalidomide and Defribotide Combination in Relapsed/Refractory Multiple Myeloma Patients.

Antonio Palumbo, MD, Alessandra Larocca, MD, Cecilia Rus, MD, Francesca Gay, MD, Davide Rossi, MD, Patrizia Pregno, MD, Patrizia Falco, MD, Ilaria Avonto, MD, Valeria Magarotto, MD, Federica Cavallo, MD, Massimo Iacobelli, MD, Gianluca Gaidano, MD, Constantine Mitsiades, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Mario Boccadoro, MD

Blood (2007) 110 (11): 2715.

https://doi.org/10.1182/blood.V110.11.2715.2715

Published: 2007

Journal Articles

A Multi-Center Phase I/II Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Avanced Multiple Myeloma Patients.

Antonio Palumbo, MD, Cecilia Rus, MD, Davide Rossi, MD, Patrizia Pregno, MD, Maria Teresa Ambrosini, MD, Ilaria Avonto, MD, Francesca Gay, MD, Federica Cavallo, MD, Massimo Iacobelli, MD, Gianluca Gaidano, MD, Constantine Mitsiades, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Mario Boccadoro, MD

Blood (2006) 108 (11): 3560.

https://doi.org/10.1182/blood.V108.11.3560.3560

Published: 2006

Journal Articles

Time to First Progression, but Not Β2-Microglobulin, Predicts Outcome in Myeloma Patients Who Received Thalidomide as Salvage Therapy.

Antonio Palumbo, MD, Sara Bringhen, MD, Patrizia Falco, MD, Cecilia Rus, MD, Federica Cavallo, MD, Maria Teresa Ambrosini, MD, Ilaria Avonto, MD, Francesca Gay, MD, Gabriele Gallone, MD, Tommaso Caravita, MD, Benedetto Bruno, MD, Mario Boccadoro, MD

Blood (2006) 108 (11): 3562.

https://doi.org/10.1182/blood.V108.11.3562.3562

Published: 2006

Journal Articles

Combination of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) for Relapsed Multiple Myeloma: Results of a Phase I/II Clinical Trial.

Antonio Palumbo, MD, Maria Teresa Ambrosini, MD, Giulia Benevolo, MD, Patrizia Pregno, MD, Norbert Pescosta, MD, Vincenzo Callea, MD, Clotilde Cangialosi, MD, Tommaso Caravita, MD, Fortunato Morabito, MD, Pellegrino Musto, MD, Sara Bringhen, MD, Francesca Gay, MD, Cecilia Rus, MD, Mario Boccadoro, MD

Blood (2006) 108 (11): 407.

https://doi.org/10.1182/blood.V108.11.407.407

Published: 2006

Journal Articles

Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial

Blood (2004) 104 (10): 3052–3057.

https://doi.org/10.1182/blood-2004-02-0408

Published: 2004

Journal Articles

Dose-Intensive Melphalan With Stem Cell Support (MEL100) Is Superior to Standard Treatment in Elderly Myeloma Patients

Antonio Palumbo, Sabrina Triolo, Chiara Argentino, Sara Bringhen, Alida Dominietto, Cecilia Rus, Paola Omedè, Corrado Tarella, Alessandro Pileri, Mario Boccadoro

Blood (1999) 94 (4): 1248–1253.

https://doi.org/10.1182/blood.V94.4.1248

Published: 1999

NARROW

A Phase I/II Trial on Melphalan, Prednisone, Thalidomide and Defribotide Combination in Relapsed/Refractory Multiple Myeloma Patients.

A Multi-Center Phase I/II Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Avanced Multiple Myeloma Patients.

Time to First Progression, but Not Β2-Microglobulin, Predicts Outcome in Myeloma Patients Who Received Thalidomide as Salvage Therapy.

Combination of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) for Relapsed Multiple Myeloma: Results of a Phase I/II Clinical Trial.

Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial

Dose-Intensive Melphalan With Stem Cell Support (MEL100) Is Superior to Standard Treatment in Elderly Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

A Phase I/II Trial on Melphalan, Prednisone, Thalidomide and Defribotide Combination in Relapsed/Refractory Multiple Myeloma Patients.

A Multi-Center Phase I/II Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Avanced Multiple Myeloma Patients.

Time to First Progression, but Not Β2-Microglobulin, Predicts Outcome in Myeloma Patients Who Received Thalidomide as Salvage Therapy.

Combination of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) for Relapsed Multiple Myeloma: Results of a Phase I/II Clinical Trial.

Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial

Dose-Intensive Melphalan With Stem Cell Support (MEL100) Is Superior to Standard Treatment in Elderly Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only